Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study

@article{Tripathy2013PioglitazoneIG,
  title={Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study},
  author={D. Tripathy and G. Daniele and T. Fiorentino and Zandra Perez-Cadena and A. Chavez-Velasquez and S. Kamath and P. Fanti and C. Jenkinson and F. Andreozzi and M. Federici and A. Gastaldelli and R. DeFronzo and F. Folli},
  journal={Diabetologia},
  year={2013},
  volume={56},
  pages={2153-2163}
}
  • D. Tripathy, G. Daniele, +10 authors F. Folli
  • Published 2013
  • Medicine
  • Diabetologia
  • Aims/hypothesisPioglitazone (PIO) is a peroxisome proliferator-activated receptor (PPAR)γ agonist insulin-sensitiser with anti-inflammatory and anti-atherosclerotic effects. Our objective was to evaluate the effect of low-dose PIO (15 mg/day) on glucose metabolism and inflammatory state in obese individuals with type 2 diabetes.MethodsA randomised, double-blind, placebo-controlled, mechanistic trial was conducted on 29 patients with type 2 diabetes treated with metformin and/or sulfonylurea… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Currently, 2-3% of the population of the United Kingdom and United States of America receive glucocorticoid therapy. Significant adverse effects are not confined to chronic use… Expand
    ConditionsIatrogenic Cushing's Disease
    InterventionDrug
    The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
    • 27

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 46 REFERENCES
    Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    • 751
    Pioglitazone for diabetes prevention in impaired glucose tolerance.
    • 560
    • PDF
    Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
    • 272
    • PDF
    Inflammation and insulin resistance.
    • 2,374
    • PDF